| Drug Type Bispecific antibody | 
| Synonyms NAV 242, NAV242 | 
| Target | 
| Action inhibitors | 
| Mechanism OX40L inhibitors(Tumor necrosis factor ligand superfamily member 4 inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Immune System Diseases | Preclinical | United States  | 01 Apr 2025 | 






